AUTOLUS LIMITED

Values shown as filed in the company's annual accounts. — indicates the figure wasn't present under that line item in that period. About these numbers

• Turnover

  +1,910.3%

  £397,000 → £7,981,000

• Cash

  -3.2%

  £172,755,000 → £167,216,000

• Net assets

  -370.7%

  -£68,648,000 → -£323,101,000

• Employees

  +11.4%

  396 → 441

• Operating profit

  -19.6%

  -£162,508,000 → -£194,425,000

• Profit before tax

  +4.5%

  -£188,904,000 → -£180,461,000

• Wages

  +8.7%

  £34,201,000 → £37,160,000

Each % is (latest − prior) ÷ |prior| for the line item as filed. The comparison is only shown when the latest and prior accounts cover broadly equal-length periods — short or long stubs (typical around incorporation or a year-end change) are suppressed rather than misrepresented. Lines a company doesn't report are omitted. About these numbers

Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Margin ratios are hidden where reported turnover is too small relative to profit to yield a meaningful figure — typical of holding companies whose income is mostly subsidiary dividends rather than trading revenue. Sector-distribution context coming next.

1. AUTOLUS LIMITED 2014-08-21 → present
2. NEWINCCO 1311 LIMITED 2014-07-03 → 2014-08-21

Accounting basis

FRS 101

Reporting scope

Standalone (parent only)

Auditor

Ernst & Young LLP

Audit opinion

Unqualified (clean)

Going concern

Affirmed

“Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the company's ability to continue as a going concern for a period to 30 September 2026.”

Significant events

• “FDA approved AUCATZYL (obecabtagene autoleucel) on 8 November 2024.”
• “Commercial launch and first sale of AUCATZYL in the United States occurred in January 2025.”
• “MHRA granted AUCATZYL conditional marketing authorization in April 2025 for UK.”
• “European Commission granted marketing authorization for AUCATZYL in July 2025 for EU.”
• “Entered into a strategic collaboration agreement and equity investment with BioNTech SE in February 2024.”
• “Paid UCLB a regulatory milestone payment of £10.0 million upon FDA approval of AUCATZYL.”

Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers

Filings

8

last 12 months

Capital events

0

last 24 months

Officers appointed

2

last 12 months

Officers resigned

2

last 12 months

Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.